… Dr Feld reported receiving financial compensation for consultancy, lecture, and development
of educational presentation activities from Hoffmann-LaRoche, Merck, Gilead, Tibotec, …

Since the identification of the hepatitis C virus, great strides have been made in the development
of an antiviral therapy. As a crucial mediator of the innate antiviral immune response, …

Background A simple treatment regimen that is effective in a broad range of patients who
are chronically infected with the hepatitis C virus (HCV) remains an unmet medical need. …

Background The interferon-free combination of the protease inhibitor ABT-450 with ritonavir
(ABT-450/r) and the NS5A inhibitor ombitasvir (also known as ABT-267) plus the …

Background Failure to generate phagocyte-derived superoxide and related reactive oxygen
intermediates (ROIs) is the major defect in chronic granulomatous disease, causing …

Viral hepatitis is a major public health threat and a leading cause of death worldwide. Annual
mortality from viral hepatitis is similar to that of other major infectious diseases such as HIV …

Background Glecaprevir and pibrentasvir are direct-acting antiviral agents with pangenotypic
activity and a high barrier to resistance. We evaluated the efficacy and safety of 8-week …

Chronic hepatitis C virus (HCV) infection is associated with several extrahepatic manifestations.
Patients with HCV may develop mixed cryoglobulinemia and its sequelae, ranging from …

Although the natural history of autoimmune hepatitis (AIH) has been characterized, little is
known about patients who present asymptomatically. Consequently, whether they require …

… Although I am not as young as Jordan Feld, I still hope I will also see the real fruits of all of
… Jordan J. Feld has received research grants from Abbvie, Boehringer-Ingelheim, Gilead …